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Introduction: Positron emission tomography (PET) with [11C]verapamil, either in racemic form or in form of
the (R)-enantiomer, has been used to measure the functional activity of the adenosine triphosphate-binding
cassette (ABC) transporter P-glycoprotein (Pgp) at the blood–brain barrier (BBB). There is some evidence in
literature that verapamil inhibits two other ABC transporters expressed at the BBB, i.e. multidrug resistance
protein 1 (MRP1) and breast cancer resistance protein (BCRP). However, previous data were obtained with
micromolar concentrations of verapamil and do not necessarily reﬂect the transporter selectivity of verapamil
at nanomolar concentrations, which are relevant for PET experiments. The aim of this study was to assess the
selectivity of verapamil, in nanomolar concentrations, for Pgp over MRP1 and BCRP.
Methods: Concentration equilibrium transport assays were performed with [3H]verapamil (5 nM) in cell lines
expressing murine or human Pgp, human MRP1, and murine Bcrp1 or human BCRP. Paired PET scans were
performed with (R)-[11C]verapamil in female FVB/N (wild-type), Mrp1(−/−), Mdr1a/b(−/−), Bcrp1(−/−) and
Mdr1a/b(−/−)Bcrp1(−/−) mice, before and after Pgp inhibition with 15 mg/kg tariquidar.
Results: In vitro transport experiments exclusively showed directed transport of [3H]verapamil in Mdr1a- and
MDR1-overexpressing cells which could be inhibited by tariquidar (0.5 μM). In PET scans acquired before
tariquidar administration, brain-to-blood ratio (Kb,brain) of (R)-[11C]verapamil was low in wild-type (1.3 ±
0.1), Mrp1(−/−) (1.4 ± 0.1) and Bcrp1(−/−) mice (1.8 ± 0.1) and high in Mdr1a/b(−/−) (6.9 ± 0.8) and
Mdr1a/b(−/−)Bcrp1(−/−) mice (7.9 ± 0.5). In PET scans after tariquidar administration, Kb,brain was
signiﬁcantly increased in Pgp-expressing mice (wild-type: 5.0 ± 0.3-fold, Mrp1(−/−): 3.2 ± 0.6-fold,
Bcrp1(−/−): 4.3 ± 0.1-fold) but not in Pgp knockout mice (Mdr1a/b(−/−) and Mdr1a/b(−/−)Bcrp1(−/−)).
Conclusion: Our combined in vitro and in vivo data demonstrate that verapamil, in nanomolar concentrations,
is selectively transported by Pgp and not by MRP1 and BCRP at the BBB, which supports the use of (R)-[11C]
verapamil or racemic [11C]verapamil as PET tracers of cerebral Pgp function.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Positron emission tomography (PET) with [11C]verapamil, either
in racemic form or in form of the (R)-enantiomer ((R)-[11C]
verapamil), has been frequently used to non-invasively study the
functional activity of the adenosine triphosphate-binding cassette
(ABC) transporter P-glycoprotein (Pgp) at the blood–brain barrier
(BBB) of animals and humans (see, for instance, Refs. [1–7]). In some
studies, Pgp function was modulated by administration of PgpEnvironment Department, AIT
tria. Tel.: +43(0) 50550 3496;
l rights reserved.inhibitors, such as cyclosporine A, valspodar or tariquidar [3–6].
Moreover, PET with [11C]verapamil has been used to assess changes in
Pgp function at the BBB occurring in neurological disorders, such as
therapy-refractory epilepsy [8], Alzheimer's disease [9] or Parkinson's
disease [10]. Surprisingly, despite its frequent use as PET tracer of
cerebral Pgp function, the selectivity of [11C]verapamil among
different ABC transporters expressed at the BBB has not been assessed
before. Knowledge about the ABC transporter selectivity of [11C]
verapamil is important, as there is a risk that PET results might be
misinterpreted due to contribution of other ABC transporters than Pgp
to [11C]verapamil efﬂux at the BBB.
Verapamil is at micromolar concentrations an inhibitor of Pgp [11].
At nanomolar concentrations verapamil is transported by Pgp [12–15]
thereby enabling PET measurement of Pgp function with tracer doses
of [11C]verapamil. It has been suggested that verapamil is not a
874 K. Römermann et al. / Nuclear Medicine and Biology 40 (2013) 873–878competitive inhibitor of Pgp but that Pgp inhibition is mediated via
another binding site than transport leading to concentration-
dependent transport of verapamil [15].
There is some evidence in the literature that verapamil also
inhibits at micromolar concentrations other ABC transporters than
Pgp, i.e. multidrug resistance protein 1 (humans: MRP1, rodents:
Mrp1) [16–18] and breast cancer resistance protein (humans: BCRP,
rodents: Bcrp1) [19]. Although verapamil itself does not appear to be
transported by MRP1 [17], one study found that the ﬂuorescent probe
bodipy-FL-verapamil is a MRP1 substrate [20].
In many cases in vitro transport data are obtained using
micromolar (i.e. therapeutically relevant) concentrations of a trans-
porter substrate and do not necessarily reﬂect the transporter
selectivity proﬁle of a compound at nanomolar concentrations,
which are relevant for in vivo PET experiments. We and others have
for instance shown that in nanomolar concentrations the Pgp
inhibitors tariquidar and elacridar are transported by Pgp and Bcrp1
at the murine BBB, but that transport is signiﬁcantly reduced when
the compounds are given in higher doses, most likely because they
dose-dependently inhibit their own transport at the BBB [21,22].
Tariquidar was found to be a dual Pgp/Bcrp1 substrate in nanomolar
and a Bcrp1-selective substrate in micromolar concentrations [21,23].
The aim of this study was to assess the selectivity of verapamil for
Pgp over MRP1 and BCRP, in nanomolar concentrations, which are
relevant for PET experiments. We used a combination of in vitro
transport assays using cell lines stably expressing murine or human
ABC transporters and in vivo PET experiments with (R)-[11C]
verapamil in wild-type and transporter knockout mice before and
after Pgp inhibition with tariquidar. By using this experimental
approach we were able to demonstrate that (R)-[11C]verapamil is
selectively transported by Pgp, and not by MRP1 and BCRP at the BBB.
2. Materials and methods
2.1. Chemicals
If not stated otherwise substances were purchased from Sigma-
Aldrich Chemie GmbH (Schnelldorf, Germany). [3H]verapamil and
[14C]mannitol (speciﬁc activity: 2.22–3.14 GBq/μmol and 1.85–
2.22 kBq/μmol, respectively) were obtained from Hartmann Analytic
GmbH (Braunschweig, Germany) and [14C]2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine ([14C]PhIP) (speciﬁc activity:
1.85 MBq/μmol) and PhIP from Toronto Research Chemicals (Toronto,
Canada). Tariquidar dimesylate was obtained from Xenova Ltd.
(Slough, UK) and MK571 from Alexis Biochemicals (Axxora, Lörrach,
Germany). For in vivo experiments, tariquidar was freshly dissolved
prior to each administration in 2.5% (wt/vol) aqueous dextrose
solution and injected intravenously (i.v.) at a volume of 4 mL/kg. For
the in vitro experiments, tariquidar and Ko143 were dissolved in
DMSO (b0.1% DMSO in ﬁnal solution) and MK571 was dissolved in
serum-free Opti-MEM® (Gibco®/Life Technologies Corporation,
Darmstadt, Germany).
2.2. Cell lines
For the in vitro transport studies LLC-PK1 cells transduced with
human MDR1 or murine Mdr1a and respective wild-type LLC cells
were used. Additionally, Madin-Darby canine kidney type II (MDCK-
II) cells transducedwithmurine Bcrp1 or human BCRP or humanMRP1Fig. 1. CETA with [3H]verapamil (5 nM) in wild-type (wt) LLC andMDCK cells (A), LLC cells t
humanMRP1 (D), murine Bcrp1 (E) or human BCRP (F) without and with respective inhibitor
MDCK cells tariquidar (0.2 μM) was added to inhibit endogenous Pgp. Additionally, control C
(2 μM) as a substrate for Bcrp1 (H) and BCRP (I). Except for control experiments (n = 1), d
apical and basolateral chamber versus time. Signiﬁcant differences are indicated by asteriskand respective wild-type MDCK-II cells were used. The cell lines were
a kind gift from Piet Borst and Alfred Schinkel (The Netherlands
Cancer Institute, Amsterdam, the Netherlands). Culturing of the cells
was performed as described earlier [24]. MDR1- and Mdr1a-over-
expressing LLC cells were regularly tested for vincristine sulfate
resistance (0.64 μM) as described before [24]. The MDCK-II cells
transducedwith Bcrp1 or BCRPwere regularly tested formitoxantrone
resistance (20 μM).2.3. Animals
Female FVB/N (wild-type), Mrp1(−/−), Mdr1a/b(−/−), Bcrp1(−/−)
and Mdr1a/b(−/−)Bcrp1(−/−) mice were obtained from Taconic Inc.
(Germantown, NY, USA). Mice were housed in groups of up to ﬁve
individuals under controlled environmental conditions (22 ± 1 °C,
40%–70% humidity) with a 12-h light–dark cycle (lights on at 6:00)
and ad libitum access to food and water. Mice underwent PET scans at
a weight of 28.2 ± 0.6 g. The study was approved by the local animal
welfare committee (Amt der Niederösterreichischen Landesregier-
ung) and all study procedures were performed in accordance with the
European Communities Council Directive of November 24, 1986 (86/
609/EEC). Every effort was made to minimize both the suffering and
the number of animals used in this study.2.4. Concentration equilibrium transport assay (CETA)
CETA was performed in triplicate as described previously [25].
With a density of 0.3 × 106 cells/cm2 LLC cells were seeded on
transparent polyester membrane ﬁlters (Transwell-Clear®, 6-well,
24-mm diameter, 0.4-μm pore size, Corning Costar Corporation,
Cambridge, MA, USA). With a density of 0.4 × 106 cells/cm2 MDCK-II
cells were seeded on translucent polyester membrane ﬁlters
(ThinCertTM, 6-well, 24.85-mm diameter, 0.4-μm pore size, Greiner
Bio-One, Frickenhausen, Germany). Transport experiments were
performed 5–7 days after the cells reached 100% conﬂuence. For 1 h
pre-incubation, culture medium was replaced by serum-free Opti-
MEM® with or without inhibitor (0.1 μM Ko143 for Bcrp1/BCRP
inhibition, 50 μMMK571 for MRP1 inhibition or 0.5 μM tariquidar for
Pgp inhibition). For experiments with MDCK-II cells tariquidar
(0.2 μM) was added for inhibition of endogenous Pgp. Incubation
was performed with [3H]verapamil in fresh Opti-MEM® on the apical
and basolateral sides of the monolayer at a concentration of 5 nM.
Samples were taken from both compartments after 60, 120, 240 and
360 min and the amount of [3H]verapamil was quantiﬁed with a β-
scintillation-counter. Control CETA was performed with calcein AM
(1 μM) for MRP1 [26] and [14C]PhIP (2 μM) for Bcrp1/BCRP. The
membrane integrity was determined by mannitol diffusion and
transepithelial electrical resistance (TEER), with criteria for exclusion
described earlier [25].2.5. Radiotracer synthesis and formulation
(R)-[11C]verapamil was synthesized as described previously [27]
and formulated for i.v. injection in phosphate-buffered saline (pH =
7.4)/ethanol (9/1, vol/vol). Radiochemical purity, as determined by
radio high-performance liquid chromatography, was greater than
98%, and speciﬁc activity at the end of synthesis was N100 GBq/μmol.ransduced with murineMdr1a (B) or humanMDR1 (C) andMDCK cells transduced with
s (tariquidar for Pgp, MK571 for MRP1 and Ko143 for Bcrp1/BCRP). In all experiments in
ETA was performed with calcein AM (1 μM) as a substrate for MRP1 (G) and [14C]PhIP
ata are shown as the mean (±SEM, n = 3) of % initial verapamil concentration in the
(*p b 0.05).
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Isoﬂurane anesthesia (1%–2% in oxygen) was induced and
maintained during the whole experimental procedure. Mice were
placed on a dual-animal bed which was kept at 38 °C to prevent
hypothermia. A catheter, placed into a lateral tail vein, was used for i.v.
administration of (R)-[11C]verapamil and tariquidar. At the beginning
of (R)-[11C]verapamil administration, dynamic PET imaging was
initiated using a microPET Focus220 scanner (Siemens Medical
Solutions, Knoxville, TN, USA). Before the ﬁrst PET scan, a transmis-
sion scan using a 57Co point source was recorded over 10 min.
Groups of FVB/N (wild-type), Mrp1(−/−), Bcrp1(−/−), Mdr1a/b(−/−)
and Mdr1a/b(−/−)Bcrp1(−/−) mice (n = 3–5 per group) underwent
paired PET scans with (R)-[11C]verapamil (injected activity: 1360 ±
74 MBq/kg in a volume of approximately 0.1 mL, corresponding to
b14 nmol/kg unlabeled (R)-verapamil) before and after administration
of tariquidar (15 mg/kg; equivalent to 18 μmol/kg) (see Fig. 2 for
diagram of study timeline). For this dose of tariquidar we have shown
complete inhibition of cerebral Pgp in an earlier study in rats [7]. One
hour after starting scan 1, tariquidar was i.v. administered over a time
period of about 1 min, followed by 90 min of PET data acquisition. Scan
2 was started at 2 h after administration of tariquidar.
As blood sampling was not feasible during the paired PET scans,
separate groups of each mouse type (n = 4–6 per group) were
injected under isoﬂurane-anesthesia with (R)-[11C]verapamil
(1210 ± 11 MBq/kg) before and after administration of tariquidar
(15 mg/kg) and venous blood was sampled at 25 min after each (R)-
[11C]verapamil injection by retro-orbital puncture. Blood samples
were weighed and measured for radioactivity in a gamma counter.
Blood radioactivity data were corrected for radioactive decay and
expressed as standardized uptake value (SUV = (radioactivity per
mL/injected radioactivity) × body weight). PET images were recon-
structed by Fourier re-binning followed by two-dimensional ﬁltered
back projection with a ramp ﬁlter. A standard data correction protocol
(normalization, attenuation and decay correction) was applied.
Whole brain was manually outlined on PET images and time–activity
curves expressed in SUV units were derived. Brain-to-blood ratios of
activity (Kb,brain) were calculated by dividing brain activity concen-
trations measured with PET at 25 min after (R)-[11C]verapamil
injection by mean blood activity concentrations measured with a
gamma counter in separate groups of mice.2.7. Statistical analysis
Statistical analyses were performed using Prism5 software
(GraphPad Inc, La Jolla, CA, USA). Data were statistically analyzed by
two-way analysis of variance (ANOVA) for CETA and by one-way
ANOVA for PET, followed by Bonferroni test to compare replicate
means (CETA) or for selected pairs of columns (PET). Tests were used
two-tailed and a p b 0.05 was considered statistically signiﬁcant. If
not stated otherwise, all values are given as mean ± standard error of
the mean (SEM).3. Results and discussion
In order to assess the ABC transporter selectivity of verapamil we
performed transport experiments with [3H]verapamil in cell lines
expressing murine or human Pgp, human MRP1, and murine Bcrp1 or
human BCRP, with and without transporter inhibition by different
inhibitors, as well as PET experiments with (R)-[11C]verapamil in
wild-type and transporter knockout mice. A similar approach has
been previously used to assess the ABC transporter selectivity of other
ABC transporter PET tracers, i.e. [11C]tariquidar, [11C]elacridar [21]
and [11C]-N-desmethyl-loperamide [28].3.1. In vitro transport experiments
As it has previously been demonstrated that the conventional
bidirectional transport assaymay often fail to identify highly permeable
compounds as transporter substrates due to their passive back-diffusion
into the donor compartment,we employedCETA, inwhich the inﬂuence
of passive diffusion is minimized by adding the drug at equal
concentrations to the apical and the basolateral compartments [25].
As there is evidence that some transporter substrates may show
different transporter selectivity proﬁles at nanomolar as comparedwith
micromolar concentrations—most likely due to concentration-depen-
dent transporter inhibition [14,15,21,22,29]—we used nanomolar
(5 nM) concentrations of [3H]verapamil in CETAwhich are comparable
to the concentrations achieved in vivo in PET experiments in blood and
in tissue. As (R)-[3H]verapamil was not commercially available we used
racemic [3H]verapamil in CETA. Wild-type LLC and MDCK cells showed
no directional transport of [3H]verapamil (Fig. 1A). In contrast, Mdr1a-
and MDR1-overexpressing cells showed signiﬁcant transport of [3H]
verapamil, which could be almost completely inhibited with tariquidar
(0.5 μM) (Fig. 1B, C). InMRP1-overexpressing cells the concentration of
[3H]verapamilwas signiﬁcantly decreased in the apical compared to the
basolateral compartment, but this was not inﬂuenced by the MRP
inhibitor MK571, indicating that this effect was not due to MRP1-
mediated transport (Fig. 1D). Control CETA performed with calcein AM
indicated that functional MRP1 was present and sensitive to inhibition
withMK571 (Fig. 1G). It should be noted that one previous study found
that the (R)- and (S)-enantiomers of verapamil had different effects on
MRP1 activity [18]. Whereas (R)-verapamil was shown to directly
inhibit MRP1, the (S)-enantiomer modulated MRP1 activity indirectly
by stimulating MRP1-mediated glutathione transport [18]. In the
present study, theuse of racemic [3H]verapamil precluded the detection
of possible differences in MRP1 interaction between (R)- and (S)-
verapamil. No signiﬁcant transport of [3H]verapamil could be detected
in Bcrp1- and BCRP-overexpressing cells (Fig. 1E, F). Control experi-
ments with [14C]PhIP demonstrated that Bcrp1 and BCRP were
functional (Fig. 1H, I).
3.2. In vivo PET experiments
As a second approach to investigate transporter selectivity of
verapamil we performed PET experiments with (R)-[11C]verapamil in
wild-type and transporter knockout mice before and after adminis-
tration of tariquidar at a dose which completely inhibits Pgp at the
BBB (Fig. 2) [7]. We have shown before that tariquidar does not
inﬂuence (R)-[11C]verapamil metabolism and plasma protein binding
[6]. We used a previously described paired scan protocol [6], in which
tariquidar was administered during the ﬁrst PET scan (i.e. at 60 min
after injection of (R)-[11C]verapamil, see Fig. 2), which allows for
directly studying the effect of tariquidar on (R)-[11C]verapamil brain
kinetics [5]. To the best of our knowledge brain distribution of [11C]
verapamil has not been assessed before in other ABC transporter
knockout mice than Pgp knockout mice [1,2].
Even though recent quantitative proteomics data indicate that
MRP1 expression levels are below the limit of quantiﬁcation at the
murine and human BBB [30], some studies have obtained evidence for
presence of functional Mrp1 activity at the murine BBB [31,32]. MRP1
is also expressed at the blood–cerebrospinal ﬂuid barrier, where it
transports its substrates from cerebrospinal ﬂuid into blood [33].
Human PET studies with (R)-[11C]verapamil have shown high uptake
of radioactivity in the choroid plexus and the ventricular system [8].
However, due to the limited spatial resolution of small-animal PET
(~1.5 mm) we were in the present study not able to analyze
distribution of (R)-[11C]verapamil into the ventricular system of
mouse brain.
Brain uptake was expressed as the brain-to-blood ratio of activity
at 25 min after injection of (R)-[11C]verapamil (Kb,brain). The time
Fig. 2.Mean (±SEM) whole-brain time–activity curves (SUV) of (R)-[11C]verapamil in wild-type (wt, n = 5, black circles),Mrp1(−/−) (n = 4, beige diamonds), Bcrp1(−/−) (n = 3,
green triangles),Mdr1a/b(−/−) (n = 3, red squares) andMdr1a/b(−/−)Bcrp1(−/−)mice (n = 3, blue triangles) for scan 1 (A) and scan 2 (B). At 60 min after start of scan 1 tariquidar
(15 mg/kg) was administered as an i.v. bolus, which is indicated by an arrow. Scan 2 was performed at 2 h after administration of tariquidar (see timeline on top of the ﬁgure). In
panels C and D, mean (±SEM) brain-to-blood ratios of activity (Kb,brain) at 25 min after (R)-[11C]verapamil injection are shown for different mouse types before (C) and after (D)
tariquidar administration. Blood activity concentrations (SUV) measured at 25 min after (R)-[11C]verapamil injection in separate groups of mice before and after tariquidar
administration are shown in panels E and F, respectively. Signiﬁcant differences are indicated by asterisk (*p b 0.05; ***p b 0.001).
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radiolabeled metabolites of (R)-[11C]verapamil to the PET signal
[34]. In scan 1 (before administration of tariquidar), Kb,brain was low in
wild-type (1.3 ± 0.1), Mrp1(−/−) (1.4 ± 0.1) and Bcrp1(−/−) mice
(1.8 ± 0.1) and high in Mdr1a/b(−/−) (6.9 ± 0.8) and Mdr1a/b(−/−)
Bcrp1(−/−) mice (7.9 ± 0.5) (Fig. 2A,C) suggesting Pgp-selective
transport of (R)-[11C]verapamil at the murine BBB. For substrates of
both Pgp and Bcrp1, such as [11C]elacridar and [11C]tariquidar [21],
disproportionally large increases in brain exposure are seen in mice
lacking both transporters (Mdr1a/b(−/−)Bcrp1(−/−) mice) relative to
single transporter knockout mice (Bcrp1(−/−) or Mdr1a/b(−/−) mice),
because of a cooperative effect of both transporters in limiting brain
entry of dual substrates [35]. For (R)-[11C]verapamil, Kb,brain was
similar in Mdr1a/b(−/−) and Mdr1a/b(−/−)Bcrp1(−/−) mice (Fig. 2C)supporting previous evidence that (R)-[11C]verapamil is not a dual
Pgp/Bcrp1 substrate [36]. In response to tariquidar injection during
scan 1, a clearly visible rise in brain time–activity curves was observed
in mice expressing Pgp (wild-type,Mrp1(−/−), Bcrp1(−/−)) but not in
mice lacking Pgp (Mdr1a/b(−/−) and Mdr1a/b(−/−)Bcrp1(−/−))
(Fig. 2A). This rise in brain time–activity curves was most likely due
to inhibition of Pgp at the BBB, resulting in inﬂux of unmetabolized
(R)-[11C]verapamil from blood into brain [6]. Similarly, in scan 2 after
tariquidar administration Kb,brain was signiﬁcantly (p b 0.001) in-
creased relative to scan 1 in Pgp-expressing mice (wild-type: 5.0 ±
0.3-fold, Mrp1(−/−): 3.2 ± 0.6-fold and Bcrp1(−/−): 4.3 ± 0.1-fold),
but not in Pgp knockout mice (Mdr1a/b(−/−) and Mdr1a/b(−/−)
Bcrp1(−/−)) (Fig. 2D), which again supported that (R)-[11C]verapamil
is selectively transported by Pgp. InMdr1a/b(−/−)Bcrp1(−/−) mice, Kb,
878 K. Römermann et al. / Nuclear Medicine and Biology 40 (2013) 873–878brain was by about 30% decreased relative to scan 1, but this did not
reach statistical signiﬁcance. Kb,brain values in scan 2 were similar for
all mouse types with the exception of Mrp1(−/−) mice, which had
signiﬁcantly lower Kb,brain values (p b 0.05) than Bcrp1(−/−) and
Mdr1a/b(−/−) mice (Fig. 2D). The exact reasons for this observation
are not known but could be for instance related to lower tariquidar
plasma concentrations (which were not measured in the present
study) in Mrp1(−/−) mice. Blood activity concentrations of (R)-[11C]
verapamil were not signiﬁcantly different amongmouse types both in
scan 1 and scan 2 and also did not differ in individual mouse types
before and after tariquidar administration (Fig. 2E, F).
4. Conclusion
Our combined in vitro and in vivo data suggest that verapamil, in
nanomolar concentrations as used for PET imaging, is selectively
transported by Pgp and not by MRP1 and BCRP at the BBB, which
supports the use of (R)-[11C]verapamil or racemic [11C]verapamil as
PET tracers of cerebral Pgp function.
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